Interview with Joanne Wilson, APRN-NP, DNP: CAR T-Cell Therapy for Solid Tumors

Interview with Joanne Wilson, APRN-NP, DNP: TIL Therapy

Welcome to the CAR T-Cell Therapy Resource Center! Here you’ll find current information, news items, highlights from the literature, case studies, and other resources that focus on CAR T-cell therapies and the advanced practitioner’s role in delivering high-quality care to our patients. If you have any feedback or questions, please contact jadpro-editor@conexiant.com.


Sarah Jimenez, DNP, AGACNP-BC, AOCNP BMT/IEC Advanced Practice Provider Blood and Marrow Transplantation/Immune Effector Cell Therapy Program Augusta University/Georgia Cancer Center	Liza Rodriguez, DNP, E-MBA, APRN, AOCNP APP Manager Hematology/Blood and Marrow Transplant Program APP Council Chair Division of Hematologic Malignancies and Cellular Therapeutics The University of Kansas Cancer Center

Educating Multidisciplinary Care Teams, Patients, and Caregivers on CAR T-Cell Therapy

SITC Clinical Practice Guideline on Immune Effector Cell-related Adverse Events

Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

American Cancer Society: CAR T-Cell Therapy and its Side Effects

NCCN: Immunotherapy Side Effects - CAR T-Cell Therapy

Stem Cells Translational Medicine

Anti-viral CD8 central memory veto cells as a new platform for CAR T cell therapy

Journal for ImmunoTherapy of Cancer

Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach

Blood Advances

Inequalities in CAR T-cell therapy access for US patients with relapsed/refractory DLBCL: A SEER-Medicare data analysis

Blood Advances

BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement

Transplantation and Cellular Therapy

Clinical experience with cranial nerve impairment in the CARTITUDE-1, CARTITUDE-2 cohorts A, B, and C, and CARTITUDE-4 studies of ciltacabtagene autoleucel (cilta-cel)

Blood Advances

Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel

Nature Medicine

Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: A phase 1 trial

Transplantation and Cellular Therapy

Neurotoxicity and rare adverse events in BCMA-directed CAR T cell therapy: A comprehensive analysis of real-world FAERS data

Blood Advances

Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma

Pediatric Blood & Cancer

Neuropsychological functioning in pediatric patients with leukemia or lymphoma treated with CAR T-cell therapy: A retrospective chart review

CAR T-Cell Therapy Resource Center

Interview with Joanne Wilson, APRN-NP, DNP: CAR T-Cell Therapy for Solid Tumors

Educating Multidisciplinary Care Teams, Patients, and Caregivers on CAR T-Cell Therapy

SITC Clinical Practice Guideline on Immune Effector Cell-related Adverse Events

Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

American Cancer Society: CAR T-Cell Therapy and its Side Effects

NCCN: Immunotherapy Side Effects - CAR T-Cell Therapy

Stem Cells Translational Medicine

Anti-viral CD8 central memory veto cells as a new platform for CAR T cell therapy

Journal for ImmunoTherapy of Cancer

Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach

Blood Advances

Inequalities in CAR T-cell therapy access for US patients with relapsed/refractory DLBCL: A SEER-Medicare data analysis

Blood Advances

BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement

Transplantation and Cellular Therapy

Clinical experience with cranial nerve impairment in the CARTITUDE-1, CARTITUDE-2 cohorts A, B, and C, and CARTITUDE-4 studies of ciltacabtagene autoleucel (cilta-cel)

Blood Advances

Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel

Nature Medicine

Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: A phase 1 trial

Transplantation and Cellular Therapy

Neurotoxicity and rare adverse events in BCMA-directed CAR T cell therapy: A comprehensive analysis of real-world FAERS data

Blood Advances

Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma

Pediatric Blood & Cancer

Neuropsychological functioning in pediatric patients with leukemia or lymphoma treated with CAR T-cell therapy: A retrospective chart review

Bloodless Medicine Management of a Patient Receiving CAR T-Cell Therapy

Transverse Myelitis With Paraplegia: An Atypical Manifestation of Neurotoxicity Following CAR T-Cell Therapy

CAR T-cell Infusion in an Outpatient Setting: An Ideal Option for Selected Patients When Available

Fast Facts #12: BCMA Targets